Publications
323
Citations
4,212
Est. group size
—
Recurring co-author estimate
Active years
14
Publishing since 2013
Nabil Adra is a medical oncology researcher focused on cancers of the urinary and reproductive systems, especially testicular (germ-cell) tumors, prostate cancer, and bladder cancer. The work centers on clinical trials of new drug treatments, chemotherapy strategies, and blood-based biomarkers (such as circulating tumor DNA) to guide therapy and detect disease relapse.
Publication activity has grown over the last decade, rising from around 12 papers in 2017 to a peak of 75 in 2024 and remaining high (about 41 per year on average over the last five years).
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~12 · 6% small-team papers (≤3 authors) · across 54 venues
- Primary Mediastinal Seminoma: Clinical Characteristics and Outcomes
Clinical Genitourinary Cancer · 2026
- Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
New England Journal of Medicine · 2026
- International Society of Urological Pathology (ISUP) Consensus Conference on Precursor Lesions
The American Journal of Surgical Pathology · 2026
- Clinical outcomes of pembrolizumab and enfortumab vedotin in variant histology urothelial carcinoma.
Journal of Clinical Oncology · 2026
- Circulating cell-free DNA profiling reveals ancestry-dependent genetic variation in metastatic prostate cancer
Molecular Biomedicine · 2026
- Overall survival from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).
Journal of Clinical Oncology · 2026
- Progression after first-line chemotherapy with normal serum tumor markers (STM) in non-seminomatous germ-cell tumors (NSGCT).
Journal of Clinical Oncology · 2026
- 910 Comparison of Transcriptomic Features of Primary Mediastinal and Testicular Germ Cell Tumors Reveals Gene Expression Correlates of Tumor Phenotype
Laboratory Investigation · 2026
- Redefining the Landscape of Genitourinary Cancer Precursors: The International Society of Urological Pathology Consensus Recommendations
European Urology · 2026
- NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026
Journal of the National Comprehensive Cancer Network · 2026
- How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer
American Society of Clinical Oncology Educational Book · 2026
- Relationships between clinical stage, pathological stage, and disease-free (DFS) survival in renal cell carcinoma as used to inform future neoadjuvant study design: ECOG-ACRIN EA8143 PROSPER analysis.
Journal of Clinical Oncology · 2026
- Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: Phase 3 KEYNOTE-905 study.
Journal of Clinical Oncology · 2026
- Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with cisplatin-ineligible muscle-invasive bladder cancer (MIBC): An analysis of clinically relevant subgroups in KEYNOTE-905.
Journal of Clinical Oncology · 2026
- Integrated clinical and genomic analysis of mediastinal germ cell tumors (GCT) with somatic transformation (SM): A multi-institutional cohort study.
Journal of Clinical Oncology · 2026
- Journal of Clinical Oncology×134
- The Journal of Urology×13
- Clinical Genitourinary Cancer×11
- Urologic Oncology Seminars and Original Investigations×9
- Annals of Oncology×7
- Jennifer King
Medicine · Indiana University
- Lawrence H. Einhorn
Medicine · Indiana University
- Clint Cary
Medicine · Indiana University
- Thomas M. Ulbright
Medicine · Indiana University
- Sandra K. Althouse
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile